β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)

  • Authors:
    • Nobunao Ikewaki
    • Vidyasagar Devaprasad Dedeepiya
    • Kadalraja Raghavan
    • Kosagi-Sharaf Rao
    • Suryaprakash Vaddi
    • Hiroshi Osawa
    • Tomohiko Kisaka
    • Gene Kurosawa
    • Subramaniam Srinivasan
    • Seydunganallu Ramasamy Balaganesa Kumar
    • Rajappa Senthilkumar
    • Masaru Iwasaki
    • Senthilkumar Preethy
    • Samuel J.K. Abraham
  • View Affiliations

  • Published online on: November 11, 2021     https://doi.org/10.3892/or.2021.8225
  • Article Number: 14
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, including diabetes, along with weakened immune systems, may ultimately lead to cancer development. Chemotherapy, radiotherapy and surgery are the mainstream approaches to treatment; however, they all lead to immune system weakness, which in turn increases the metastatic spread. The aim of the present review was to provide evidence of a biological response modifier β‑glucan [β‑glucan vaccine adjuvant approach to treating cancer via immune enhancement (B‑VACCIEN)] and its beneficial effects, including vaccine‑adjuvant potential, balancing metabolic parameters (including blood glucose and lipid levels), increasing peripheral blood cell cytotoxicity against cancer and alleviating chemotherapy side effects in animal models. This suggests its value as a potential strategy to provide long‑term prophylaxis in immunocompromised individuals or genetically prone to cancer.
View References

Related Articles

Journal Cover

January-2022
Volume 47 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ikewaki N, Dedeepiya VD, Raghavan K, Rao K, Vaddi S, Osawa H, Kisaka T, Kurosawa G, Srinivasan S, Kumar SR, Kumar SR, et al: β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review). Oncol Rep 47: 14, 2022
APA
Ikewaki, N., Dedeepiya, V.D., Raghavan, K., Rao, K., Vaddi, S., Osawa, H. ... Abraham, S.J. (2022). β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review). Oncology Reports, 47, 14. https://doi.org/10.3892/or.2021.8225
MLA
Ikewaki, N., Dedeepiya, V. D., Raghavan, K., Rao, K., Vaddi, S., Osawa, H., Kisaka, T., Kurosawa, G., Srinivasan, S., Kumar, S. R., Senthilkumar, R., Iwasaki, M., Preethy, S., Abraham, S. J."β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)". Oncology Reports 47.1 (2022): 14.
Chicago
Ikewaki, N., Dedeepiya, V. D., Raghavan, K., Rao, K., Vaddi, S., Osawa, H., Kisaka, T., Kurosawa, G., Srinivasan, S., Kumar, S. R., Senthilkumar, R., Iwasaki, M., Preethy, S., Abraham, S. J."β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)". Oncology Reports 47, no. 1 (2022): 14. https://doi.org/10.3892/or.2021.8225